Nocardia rubra cell-wall skeleton activates an immune response in cervical tissue via stimulating FPR3 to enhance dendritic cell-mediated Th1 differentiation

Front Immunol. 2023 Mar 2:14:1117545. doi: 10.3389/fimmu.2023.1117545. eCollection 2023.

Abstract

Nocardia rubra cell wall skeleton (Nr-CWS) has proven to be a successful medicine for therapy of cervical human papillomavirus infection. The mechanism of action of Nr-CWS is unclear but may involve a stimulatory effect on the host immune system. We previously found that CD4+ T cells were increased in cervical tissue after Nr-CWS treatment. Microarray data from these cervical tissues revealed the significant upregulation of formylated peptide receptor 3 (FPR3). This study aimed to explore the role of Nr-CWS in immunomodulatory based on these findings. Examination of CD4+ T cell subsets in cervical tissue from patients who received Nr-CWS revealed substantial increases in Th1 cytokines and transcription factors. The regulatory effects of Nr-CWS on the function and phenotype of dendritic cells (DCs) were assessed in comparison with the traditional DC maturation inducer lipopolysaccharide (LPS). Similar to LPS, Nr-CWS potently induced DC maturation and interleukin-12 (IL-12) secretion. Differentiation of T cells induced by Nr-CWS stimulated DCs was assessed using the mixed lymphocyte reaction assay. Significant differentiation towards Th1 was evident. Finally, FPR3 expression in DCs in response to Nr-CWS and LPS was measured. Nr-CWS potently upregulated FPR3 expression, while the LPS did not. Silencing FPR3 in DCs reduced Nr-CWS-induced IL-12 production and Th1 cell polarization in co-cultured T cells. The collective findings indicate that Nr-CWS may target FPR3 on the surface of DC cells and activate a Th1-type immune response. The findings clarify the basis of the antiviral immune effects of Nr-CWS on human papillomavirus.

Keywords: Th1 cell polarization; cervical intraepithelial neoplasia (CIN); dendritic cells (DCs); formyl peptide receptor 3 (FPR3); human papillomavirus (HPV); immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Differentiation
  • Cell Wall Skeleton*
  • Cervix Uteri*
  • Dendritic Cells* / immunology
  • Female
  • Humans
  • Immunity
  • Interleukin-12 / metabolism
  • Lipopolysaccharides
  • Receptors, Peptide / metabolism
  • Th1 Cells / immunology

Substances

  • Cell Wall Skeleton
  • Interleukin-12
  • Lipopolysaccharides
  • Receptors, Peptide
  • FPR3 protein, human

Supplementary concepts

  • Rhodococcus ruber

Grants and funding

This work was supported by the National Key Research and Development Program of China (Program Nos. 2022YFC2704400), and the Natural Science Foundation of Hebei Province (Grant No. H2020206243).